Abbott's Medical Devices segment grew 9.0% on a reported basis in the second quarter, driven by double-digit gains in Electrophysiology and high-single-digit growth in Diabetes Care. Electrophysiology sales rose 14.0% reported and 13.4% comparable, supported by the company's pulsed field ablation portfolio. Continuous glucose monitor sales grew 11.0% reported and 9.5% comparable. In May, Abbott secured CE Mark for Libre Duo, which it calls the world's first dual glucose-ketone biowearable sensor. The company also presented late-breaking clinical data at the Heart Rhythm Society conference in April that it said showed strong clinical outcomes across its pulsed field ablation and conduction system pacing portfolios.

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.

(END) Dow Jones Newswires

July 16, 2026 08:19 ET (12:19 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.